BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32483379)

  • 1. Identification of a potent and selective covalent Pin1 inhibitor.
    Pinch BJ; Doctor ZM; Nabet B; Browne CM; Seo HS; Mohardt ML; Kozono S; Lian X; Manz TD; Chun Y; Kibe S; Zaidman D; Daitchman D; Yeoh ZC; Vangos NE; Geffken EA; Tan L; Ficarro SB; London N; Marto JA; Buratowski S; Dhe-Paganon S; Zhou XZ; Lu KP; Gray NS
    Nat Chem Biol; 2020 Sep; 16(9):979-987. PubMed ID: 32483379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
    Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
    Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An irreversible inhibitor of peptidyl-prolyl cis/trans isomerase Pin1 and evaluation of cytotoxicity.
    Ieda N; Itoh K; Inoue Y; Izumiya Y; Kawaguchi M; Miyata N; Nakagawa H
    Bioorg Med Chem Lett; 2019 Feb; 29(3):353-356. PubMed ID: 30585173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1).
    Liu L; Zhu R; Li J; Pei Y; Wang S; Xu P; Wang M; Wen Y; Zhang H; Du D; Ding H; Jiang H; Chen K; Zhou B; Yu L; Luo C
    J Med Chem; 2022 Feb; 65(3):2174-2190. PubMed ID: 35089030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.
    Dubiella C; Pinch BJ; Koikawa K; Zaidman D; Poon E; Manz TD; Nabet B; He S; Resnick E; Rogel A; Langer EM; Daniel CJ; Seo HS; Chen Y; Adelmant G; Sharifzadeh S; Ficarro SB; Jamin Y; Martins da Costa B; Zimmerman MW; Lian X; Kibe S; Kozono S; Doctor ZM; Browne CM; Yang A; Stoler-Barak L; Shah RB; Vangos NE; Geffken EA; Oren R; Koide E; Sidi S; Shulman Z; Wang C; Marto JA; Dhe-Paganon S; Look T; Zhou XZ; Lu KP; Sears RC; Chesler L; Gray NS; London N
    Nat Chem Biol; 2021 Sep; 17(9):954-963. PubMed ID: 33972797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4,6-bis(benzyloxy)-3-phenylbenzofuran as a novel Pin1 inhibitor to suppress hepatocellular carcinoma via upregulating microRNA biogenesis.
    Fan X; He H; Li J; Luo G; Zheng Y; Zhou JK; He J; Pu W; Zhao Y
    Bioorg Med Chem; 2019 Jun; 27(11):2235-2244. PubMed ID: 31027708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.
    Campaner E; Rustighi A; Zannini A; Cristiani A; Piazza S; Ciani Y; Kalid O; Golan G; Baloglu E; Shacham S; Valsasina B; Cucchi U; Pippione AC; Lolli ML; Giabbai B; Storici P; Carloni P; Rossetti G; Benvenuti F; Bello E; D'Incalci M; Cappuzzello E; Rosato A; Del Sal G
    Nat Commun; 2017 Jun; 8():15772. PubMed ID: 28598431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Pin1 in the development and treatment of cancer.
    Min SH; Zhou XZ; Lu KP
    Arch Pharm Res; 2016 Dec; 39(12):1609-1620. PubMed ID: 27572155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel thiazole-based derivatives as human Pin1 inhibitors.
    Du L; Wang X; Cui G; Xu B
    Bioorg Med Chem; 2021 Jan; 29():115878. PubMed ID: 33246256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors.
    Cui G; Jin J; Chen H; Cao R; Chen X; Xu B
    Bioorg Med Chem; 2018 May; 26(8):2186-2197. PubMed ID: 29576270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
    Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
    Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed Lineage Kinase 3 phosphorylates prolyl-isomerase PIN1 and potentiates GLI1 signaling in pancreatic cancer development.
    Viswakarma N; Sondarva G; Principe DR; Nair RS; Kumar S; Singh SK; Das S; Sinha SC; Grippo PJ; Grimaldo S; Giulianotti PC; Rana B; Rana A
    Cancer Lett; 2021 Sep; 515():1-13. PubMed ID: 34052323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of Novel Benzimidazole Derivatives as Pin1 Inhibitors.
    Wang S; Guan L; Zang J; Xing K; Zhang J; Liu D; Zhao L
    Molecules; 2019 Mar; 24(7):. PubMed ID: 30934730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and function of the human parvulins Pin1 and Par14/17.
    Matena A; Rehic E; Hönig D; Kamba B; Bayer P
    Biol Chem; 2018 Jan; 399(2):101-125. PubMed ID: 29040060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer.
    Russo Spena C; De Stefano L; Palazzolo S; Salis B; Granchi C; Minutolo F; Tuccinardi T; Fratamico R; Crotti S; D'Aronco S; Agostini M; Corona G; Caligiuri I; Canzonieri V; Rizzolio F
    J Control Release; 2018 Jul; 281():1-10. PubMed ID: 29746956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
    Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
    Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peptidyl prolyl isomerase, PIN1 induces angiogenesis through direct interaction with HIF-2α.
    Choi MA; Saeidi S; Han HJ; Kim SJ; Kwon N; Kim DH; Min SH; Choi BY; Surh YJ
    Biochem Biophys Res Commun; 2020 Dec; 533(4):995-1003. PubMed ID: 33012513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H-Ras induces Nrf2-Pin1 interaction: Implications for breast cancer progression.
    Saeidi S; Kim SJ; Han HJ; Kim SH; Zheng J; Lee HB; Han W; Noh DY; Na HK; Surh YJ
    Toxicol Appl Pharmacol; 2020 Sep; 402():115121. PubMed ID: 32621833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.